Saliva for COVID-19 testing: simple but useless or an undervalued resource? by Pijuan-Galito, S et al.
PERSPECTIVE
published: 15 December 2021
doi: 10.3389/fviro.2021.778790
















This article was submitted to
Emerging and Reemerging Viruses,
a section of the journal
Frontiers in Virology
Received: 17 September 2021
Accepted: 26 October 2021
Published: 15 December 2021
Citation:
Pijuan-Galito S, Tarantini FS, Tomlin H,
Jenkins H, Thompson JL, Scales D,
Stroud A, Tellechea Lopez A,
Hassall J, McTernan PG, Coultas A,
Arendt-Tranholm A, Reffin C, Hill I,
Lee I-n, Wu S, Porte J, Chappell J,
Lis-Slimak K, Kaneko K, Doolan L,
Ward M, Stonebridge M, Ilyas M,
McClure P, Tighe P, Gwynne P,
Hyde R, Ball J, Seedhouse C,
Benest AV, Petrie M and Denning C
(2021) Saliva for COVID-19 Testing:
Simple but Useless or an Undervalued
Resource? Front. Virol. 1:778790.
doi: 10.3389/fviro.2021.778790
Saliva for COVID-19 Testing: Simple
but Useless or an Undervalued
Resource?
Sara Pijuan-Galito 1, Francesco Saverio Tarantini 1, Hannah Tomlin 1, Harry Jenkins 1,
Jamie Louise Thompson 1, Danielle Scales 1, Amy Stroud 1, Ana Tellechea Lopez 1,
James Hassall 2, Philip G. McTernan 3, Andy Coultas 4, Asta Arendt-Tranholm 1,
Caroline Reffin 1, Ian Hill 1, I-ning Lee 1, Siyu Wu 1, Joanne Porte 1, Joseph Chappell 2,
Katarzyna Lis-Slimak 1, Kazuyo Kaneko 1, Lara Doolan 1, Mairead Ward 1,
Martin Stonebridge 1, Mohammad Ilyas 1, Patrick McClure 2, Patrick Tighe 2,
Penny Gwynne 1, Ralph Hyde 1, Jonathan Ball 2, Claire Seedhouse 1, Andrew V. Benest 1,
Moira Petrie 1 and Chris Denning 1* on behalf of The University of Nottingham COVID-19
Asymptomatic Testing Service
1 Biodiscovery Institute, University of Nottingham, Nottingham, United Kingdom, 2 Faculty of Medicine and Health Sciences,
University of Nottingham, Nottingham, United Kingdom, 3 School of Science and Technology, Nottingham Trent University,
Nottingham, United Kingdom, 4Department of Clinical Microbiology, Kings Mill Hospital, Sutton-in-Ashfield, United Kingdom
During the COVID-19 pandemic, countries with robust population-based asymptomatic
testing were generally successful in controlling virus spread, hence reducing
hospitalizations and deaths. This effectiveness inspired widespread asymptomatic
surveillance for COVID-19/SARS-CoV-2 globally. Polarized vaccination programs,
coupled with the relatively short-lived immunity vaccines provide, mean that reciprocal
cross-border exchanges of each new variant are likely, as evidenced by Delta and
Gamma, and asymptomatic testing will be required for the foreseeable future. Reliance
on nasopharyngeal swabs contributes to “testing fatigue” arising due to difficulties in
standardizing administration, unpleasantness, and inappropriateness of use in younger
people or individuals with special needs. There has also been erosion in confidence of
testing due to variable and/or poor accuracy of lateral flow devices to detect COVID-
19. Here, we question why saliva-based PCR assays are not being used more widely,
given that standardization is easy and this non-invasive test is suitable for everyone,
providing high sensitivity and accuracy. We reflect on our experience with the University
of Nottingham COVID-19 Asymptomatic Testing, where (as of October 2021) 96,317
samples have been processed by RT-qPCR from 23,740 repeat saliva donors, yielding
465 positive cases. We challenge myths that saliva is difficult to process, concluding
that it is an undervalued resource for both asymptomatic and symptomatic detection of
SARS-CoV-2 genomes to an accuracy of >99% and a sensitivity of 1–10 viral copies/µl.
In July 2021, our data enabled Nottingham to become the first UK University to gain
accreditation and the first UK institute to gain this accolade for saliva.
Keywords: SARS-CoV-2, lateral flow, polymerase chain reaction, COVID-19, nasopharyngeal swab, saliva,
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INTRODUCTION
Since the first reports of SARS-CoV-2 infections in late 2019,
there has been an emerging acceptance of the need to co-exist
with the virus in our communities. Outbreak control will be
critical, requiring large-scale testing for the foreseeable future,
well beyond mass vaccination programs. General population
surveillance provides valuable real-time data on infection rates,
spread, and demographics (1). The importance of monitoring
new variants, prevalence, and capacity for evasion of immunity is
highlighted by Delta and Gamma variants (2), and now Delta+.
By August 2021, 70% of the 3 billion vaccines produced were
delivered in just 10 countries vs. 1% in the developing world. New
variants will emerge from what the World Health Organization
has dubbed a “two-tier pandemic”, hence perpetuating cycles
of reinfection1.
For SARS-CoV-2 detection, public testing schemes typically
rely on nasopharyngeal swabs for lateral flow or polymerase
chain reaction tests (LFTs or PCR, respectively). With high
specificity and sensitivity (circa 95–99%), PCR approaches are
the mainstay of COVID-19 tests, employing extraction of RNA
followed by reverse transcriptase quantitative PCR (RT-qPCR)
or loop mediated isothermal amplification (LAMP). LFTs detect
epitopes in the viral spike protein, giving sensitivities of 5%−70%
relative to RT-qPCR detection of the SARS-CoV-2 genome (3, 4).
Detection limit of LFTs is circa 100 viral copies/µl (5), 10- to
100-fold less sensitive than PCR approaches.
Discussion continues on the relative merits of each
approach regarding cost, labor, route of deployment, and
result turnaround. However, a common issue is the use of
nasopharyngeal swabs (6). A pervasive error exists in the
failure to reach the correct nasopharynx target site, even when
performed by trained medical experts (7, 8). Inexperienced or
self-administered operators have LFT sensitivities of sub-50%,
with uncertainty on how far “up” or “back” the swab should
go or at what “angle” and for “how long”. At best, this causes
discomfort because the swab is wedged against the middle
turbinate (7), dissuading regular repeat testing. At worst, false-
negative results lead to relaxed behaviors that amplify virus
transmission. Indeed, numerous people with overt COVID-19
symptoms report that they have tested negative viamultiple LFTs
over consecutive days but positive by RT-qPCR approaches.
OVERLOOKED BENEFITS OF SALIVA FOR
SARS-COV-2 DETECTION
The purpose of this Perspective is to prompt discussion and
highlight saliva-based direct RT-qPCR detection of SARS-CoV-
2 as an alternative method, thus far overlooked for mainstream
testing. Saliva samples avoid the issues of invasive, qualitative
nasopharyngeal swabs by easy provision, less variability and
more reliability because volumes of 100 µl are acceptable.
Anecdotally, samples provided in the morning before eating
food, brushing teeth, or using oral hygiene products, such as
mouth wash, provide high-quality samples. Our Asymptomatic
1https://www.nature.com/articles/d41586-021-01390-4
Testing Service2. (University ethics approval committee approval
FMHS 96-0920) is currently evaluating if simplified collection
routes benefit sensitive communities, such as special education,
dementia patients, homeless hostels, or victims of sexual abuse,
where any perceived penetration is unwelcome.
Other benefits of direct saliva-based RT-qPCR detection are
as follows: (i) Reduced risk of infection to the staff conducting
the sampling, since self-harvesting is easy. (ii) Sample stability;
at least 20 days at 4◦C without viral transport medium (see
Figure 1). (iii) No RNA-extraction step, decreasing testing time
and cost. (iv) Possibility of sample pooling to increase throughput
and reduce cost. (v) Not competing with other diagnostic
schemes, hence increasing capacity without additional demand
onmanufacturers. (vi) Fewer components, reducing supply chain
issues, the importance of which was highlighted during the
worldwide shortage of nasopharyngeal swabs (9). (vii) High
specificity/sensitivity comparable with nasopharyngeal swab-
based detection (3, 6, 10–12).
Underscoring these benefits, from November 2020 to
February 2021, the University of Nottingham provided free
access to undergraduate students (typically 18–22-year-olds)
of LFTs using nasopharyngeal swabs (provided by the UK
Government) and RT-qPCR testing using saliva collection aids
(provided by our Service). Circa 20,000 tests were completed,
with evidence citing ease, reliability, and confidence in the result
for why there was a preference toward saliva tests (13).
Why saliva is underutilized is unclear, though it may be
due to historical reasons and paucity of data in the literature
on accuracy. Indeed, nearly a year into the pandemic (late
2020), the Infectious Diseases Society of America guidelines
stated that “saliva as the sole sample source for COVID-19
diagnosis cannot be recommended due to a paucity of studies”
(14). However, other studies have shown high sensitivity of
SARS-CoV-2 detection using saliva, wherein there was a higher
correlation with care worker-collected nasopharyngeal swabs
than self-sampled anterior nasal swabs (15–17). Another factor is
the small sample size and unclear saliva sampling methodology,
no doubt being an underlying cause of the conflict on the level of
correlation with nasopharyngeal swab3.
Within our own service, the issues associated with saliva
as a diagnostic sample are modest relative to benefits. For
example, while we overcame potential background fluorescence
issues by using double-quenched probes from IDT (internal
ZEN quencher at 9 base pairs from 5’ end; IowaBlack Quencher
at 3’ end), the level of complementarity between the N1
and E primer/probe sets (and/or amplicons) caused aberrant
amplification curves, which could only be overcome switching to
a combination of N2 and E. We have also found that sequencing
the viral genome from saliva can be a challenge, possibly due to
fragmented viral RNA.
Impurities and inhibitors within saliva may be problematic
but can be overcome if processed in conjunction with compatible
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FIGURE 1 | Saliva-based RT-qPCR detection of SARS-CoV-2 is a reliable diagnostic method. (A) A Stepwise testing process: (i) Self-sampling of saliva into a
barcoded vial; (ii) Donor scans barcode using their personal devices (e.g., smartphone) and enter information to secure database; (iii) Batch inactivation and lysis for
(Continued)
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FIGURE 1 | 5min at 95◦C in an oven; (iv) Robot-assisted two-way pooling into 96- or 384-well plates; (v) Direct RT-qPCR to target genes; (vi) Data analysis; (vii)
Deconvolution of positive samples to allow (viii) re-testing of original saliva as single samples in a new RT-qPCR cycle; (ix) Automated reporting via Achiever Medical
LIMS, Interactive software. (B) Correlation of positive results from our saliva test vs. a UK government-approved swab-based testing service known as a “Pillar II” test.
Of 50 patients identified as positive using our testing method, 94% tested positive via Pillar II. (C) Assay reproducibility shown as the plotted Ct values for a positive
sample tested repeatedly over 14 days using four different qPCR machines by four different operators (n = 18). (D) Plotted prevalence (% of detected positive
samples over total samples tested) over time (weeks, red circles) against the number of total samples processed each week (blue squares). (E) Plotted prevalence (%
of detected positive samples over total samples tested) in our cohort over time (weeks, red circles) and the prevalence (%) of positive samples detected by the local
public healthcare system (gray diamonds). The data for the prevalence (%) of positive SARS-CoV-2 diagnostic tests were sourced from a UK government site. (F)
Stability of saliva was evaluated via regular repeat analysis of 12 samples stored at 4◦C for up to 20 days via RT-qPCR amplifying viral genes N1 (n = 9), N2 (n = 3), or
E (n = 3), or the internal control human gene, RP (RNAseP; n = 3). High stability was observed over the time course, with all standard deviations (SD) being ≤1.1 and
coefficients of variation (CoV) being <5%. Dataset consistency was confirmed using Kolmogorov–Smirnov normality test (normality test passed, p < 0.05).
pooling presents the greatest challenge to sensitivity due to a
skewed ratio of impurities vs. viral genomes per unit volume.
While we have found the limit of detection in single saliva
samples is <1 viral genome/µl, the maximum sensitivity in
eight samples combined in two-way pools reduced to 4 viral
genomes/µl. Impact on samples of samples with medium to
low viral loads is negligible, but when Ct values exceed 30, the
error rate of detection in pooled samples reduces accuracy to
<99%. Although this level is required by UK regulatory agencies
for diagnosis of SARS-CoV-2, saliva is an attractive sample,
especially when mass surveillance is needed during easing of
social distancing and travel bans.
AN EVIDENCE-BASED PIPELINE FOR
SARS-COV-2 DETECTION USING SALIVA
The simple, streamlined pipeline we use is in Figure 1A, while
Figures 1B–E show data generated between September 2020 and
July 2021 from regular testing among University of Nottingham
staff, students, and support services. At time of writing (October
2021), circa 96,317 samples were processed from 23,740 unique
donors, yielding 465 positive test results. Key aspects are
as follows.
Harvesting
Donors are provided with a Ziploc bag containing a collection
tube (dual linear and QR bar codes; Brooks Ltd, product
[65-7643]), tissue, paper straw (cut to lengths of ∼5 cm;
purchased via Amazon from IntrinsicPaperStraws.com, item
Black 6 × 140mm), and a stepwise guide4. To avoid exogenous
contaminants, donors are requested to provide a saliva sample in
the morning before they have eaten, brushed their teeth, or used
oral hygiene products, consistent with the guidelines from the
European Center for Disease Prevention and Control (ECDC)
(see footnote 3).
Inactivation
Saliva samples are oven-baked to a target temperature of
95◦C/5min to inactivate and lyse virus, hence simplifying safety
procedures and bypassing the need for toxic chemicals and/or
RNA extraction. While, at least in our experience, heating causes
4https://www.nottingham.ac.uk/coronavirus/university-testing-service/how-to-
provide-your-sample/how-to-get-tested.aspx
swabs and/or viral transport medium to become more viscous,
with saliva, the effect is to increase sample fluidity. This is critical,
yet often overlooked because of compatibility with downstream
liquid handling processes.
Pooling, Then RT-qPCR
When prevalence of infection is low (<6%), samples are
configured into two-way pools of six to eight samples per
pool for one-step RT-qPCR with Center for Disease Control
(CDC) primer-probes for the N and/or E genes. Critical points
are as follows: (i) Quantabio UltraPlex 1-Step ToughMix RT-
qPCR Reagents, designed for use with samples containing high
levels of potential inhibitory factors. (ii) Positive pooled samples
are deconvoluted and confirmed via single, unpooled tests. If
prevalence exceeds 6%, the complexity of deconvolution becomes
prohibitive and the process pipeline defaults to single, non-
pooled testing.
In support of saliva in surveillance and diagnosis of SARS-
CoV-2 infection, we provide illustrative data from the University
of Nottingham Asymptomatic Testing Service. Figure 1B shows
that of samples identified as positive in our assay, 94%
agreement correlation (95% CI 87.2–100.8) existed with a
hospital-accredited swab-based qPCR service. The 6% differential
might be explained by saliva being a more consistent sample
to harvest, as explored above. Also, 1–5 days elapsed between
positive saliva result and the swab provision; hence, viral load
may have reduced.
Saliva tests showed high intra-assay precision after repeat
testing of the same positive samples over 14 days between
four different operators and four different qPCR machines
(Figure 1C). The high concordance required to satisfy the
regulators and achieve accreditation (see below) suggests that
heat inactivation has little or no negative effect on sensitivity
and, anecdotally, may increase sensitivity in some cases. This
is possibly because there is no loss of viral RNA, which
occurs to varying degrees when using extraction procedures. In
Figures 1D,E, an increased number of samples were tested from
people on campus associates with reducing prevalence rates in
staff and students (1D) and with 10–100-fold lower infection
rates than the surrounding geographical area of Nottingham
(1E, data from UK government). These data suggest that
early detection is breaking transmission chains, even in high-
population zones such as student halls of residence.
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DISCUSSION
Combined with the few data available in the literature, our
work on SARS-CoV-2 RT-qPCR detection points to saliva
as an undervalued resource. Via this Perspective, we seek
to promote discussion around the potential for a missed
opportunity to achieve COVID-19 surveillance and outbreak
control. The perception that saliva is difficult to work
with can be overcome by simple modifications, such as by
heating and using one-step inhibitor-resistant RT-qPCR. To
assist with appropriate harvesting approaches, the European
Center for Disease Prevention and Control (ECDC) recently
published (17) a technical report “Considerations for the use
of saliva as sample material for COVID-19 testing”. Although
concluding that saliva sample collection is easy, non-invasive,
acceptable for repeat testing, and can be performed by non-
healthcare professionals, ECDC noted that performance of
RT-qPCR tests has variously reported both higher and lower
sensitivity for saliva samples compared with nasopharyngeal
swabs. In part, heterogeneity is likely to reflect differences
in sampling techniques, sampling times, and the type of
population being tested, which the ECDC technical report
explores (17).
Within the guidance from ECDC is the need to provide
a sample into a “collection container, upon waking up,
before brushing teeth and eating”. We came to the same
conclusions early on in the UoN Testing Service because saliva
samples of various consistencies and viscosities slowed down
testing and processing time. Sample provision before eating
is likely to be one factor in the high accuracy, sensitivity,
and consistency observed within the UoN Testing Service
and in other laboratories, which have reported that saliva
has offered greater sensitivity than nasopharyngeal swabs for
diagnosis of asymptomatic and mild COVID-19 infection
(11). Retrospective studies have provided similar findings.
Guillaume and colleagues (12) surveyed 385 references, which
yielded 16 unique studies that were identified for quantitative
synthesis. Eight peer-reviewed studies and eight preprints were
included in the meta-analyses (5,922 unique patients), with a
conclusion that diagnostic accuracy of saliva is similar to that of
nasopharyngeal swabs.
Other benefits include ease of donation, minimal invasiveness,
high-sensitivity testing, and accurate reporting. Stability of
saliva as a source material is also high (Figure 1F), wherein
regular analysis via RT-qPCR to N1, N2, E, and/or RNAseP
of the same samples stored at 4◦C for up to 20 days
showed standard deviations (SD) of ≤1.1 and coefficients
of variation (CoV) of <5%. These attributes meant that
saliva samples were preferred over nasopharyngeal swabs
within our cohorts, and we expect the same to be true for
communities with special considerations; hence, the assay will
increase inclusivity.
In July 2021, the University of Nottingham became the
first university in the UK and the first institution in the
UK to gain accreditation status from the oversight body,
UKAS (UK Accreditation Service). This permitted results
from our testing service to be reported directly to the
government organization, Public Health England, thereby
requiring donors who are positive for SARS-CoV-2 to follow
national laws. At the time of writing (October 2021), all
datasets in the form of research and protocols manuscripts
are being prepared to give detailed information on the use
of a triplex testing via CDC primers N2 and E, along with
an internal control of RNAseP, in SARS-CoV-2 detection in
saliva following direct heat inactivation. In these articles, we
will draw on evidence from circa 100,000 samples tested.
This will include data required for UKAS accreditation
showing >99% concordance of 400 samples (250 negative
and 150 positive), most of which were twinned swab and
saliva hospital samples. We will provide evidence for analytical
specificity, analytical sensitivity (limit of detection), limit of
quantification, diagnostic specificity, diagnostic sensitivity,
precision, sample stability, repeatability, reproducibility,
range/linearity/accuracy, robustness (control of known
interference), and low coefficients of variation of ≤5.3%
even in the most viscous saliva samples.
Receiving accreditation from UKAS means that we can assist
other institutions to gain this accolade and both accelerate
and broaden their own testing programs. In parallel, the US
Food & Drug Administration (FDA) approved Emergency
Use Authorization (EUA) for “SalivaDirectTM” (18). Various
saliva RT-qPCR tests are in development or in the process of
regulatory approval through the FDA EUA process or the CE
Marking process in the European Union, including Rutgers
University, OraSure Technologies/DNA Genotek, University of
Illinois Champagne, and others. In instances where community
surveillance requires pooling of large numbers of samples
(10 or more per pool), there is the potential that viscosity
may cause pipetting errors or reduce the sensitivity of
SARS-CoV-2 detection, especially when using direct RT-qPCR
approaches on samples with low viral loads (17). These issues
can be overcome by extracting viral RNA prior to pooling
and analysis but may not be needed due to differences
in regulatory bodies. In the UK, regulations permit only a
maximum of four samples to be pooled for diagnostic purposes
for SARS-CoV-2.
Saliva may not be a one-size-fits-all solution. While various
companies now offer saliva-based antigen or antibody tests,
the ECDC suggests that the current limited evidence does not
support the use of this sample material in this way and further
clinical validation studies are needed on the different available
tests (17). Nevertheless, even if this stance does not change
for protein-based testing, the acceptability and ease of saliva
as a donor sample coupled with approval as a diagnostic for
SARS-CoV-2 genomes by multiple regulatory bodies, including
the FDA, ECDC, and UKAS, is positive. This is likely to assist
with sustained regular repeat testing over long periods, which
will be essential to detect emergence of new variants during
this two-tier pandemic. Thus, to conclude, saliva is presented
as a suitable first-line diagnostic test to survey and control
infection rates among populations in a more efficient and
less invasive manner, complementing other testing strategies
and improving our ability to control infectious events in
the future.
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